Health-related quality of life and treatment satisfaction and preference in a community assessment study of extended-release mixed amphetamine salts for children with attention-deficit/hyperactivity disorder

Journal of Outcomes Research

Volumn 8, Issue 27-49, 2004, Pages 27-49

  Sallee, F Randy ^a,e   Ambrosini, Paul J ^b   Lopez, Frank A ^c   Shi, Li ^d   Michaels, M Alex ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Children's Development Center   (United States)

^d Shire Pharmaceutical Devmt Inc   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Amphetamine; Attention deficit hyperactivity disorder; Children; Health related quality of life; School aged; Stimulant; Treatment preference; Treatment satisfaction

Indexed keywords

ADDERAL XR; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; MANIFAXINE; METHYLPHENIDATE; NORADRENALIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; COMMUNITY CARE; COMPARATIVE STUDY; CONNERS GLOBAL INDEX SCORE PARENT VERSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MENTAL INSTABILITY; MULTICENTER STUDY; NERVOUSNESS; OPEN STUDY; PARENT; PATIENT SATISFACTION; PEDIATRIC QUALITY OF LIFE INVENTORY; POPULATION RESEARCH; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE PREPARATION; TABLET; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

EID: 9144222889     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association Press, 1994.
2. Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-113.
3. Barkley RA, Fischer M, Edelbrock CS, Smallish L. The adolescent outcome of hyperactive children diagnosed by research criteria: 1. An 8-year prospective follow-up study. Journal of the American Academy of Child and Adolescent Psychiatry 1990; 29: 546-557.
4. Heiligenstein E, Conyers LM, Berns AR et al. Preliminary normative data on DSM-IV attention deficit hyperactivity disorder in college students. Journal of American College Health 1998; 46: 185-188.
5. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. Comprehensive Psychiatry 1996; 37: 393-401.
6. Mannuzza S, Klein RG, Bessler A et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Archives of General Psychiatry 1993; 50: 565-576.
7. Barkley RA, Guevremont DC, Anastopoulos AD et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 1993; 92: 212-218.
8. Mannuzza S, Klein RG, Konig PH et al. Hyperactive boys almost grown up. IV. Criminality and its relationship to psychiatric status, Archives of General Psychiatry 1989; 46: 1073-1079.
9. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. Journal of Clinical Psychiatry 1998; 59 (Suppl 7): 50-58.
10. DiScala C, Lescohier I, Barthel M et al. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102: 1415-1421.
11. Swensen AR, Birnbaum HG, Secnik K et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 1415-1423.
12. Chan E, Zhan C, Homer CJ. Health care use and costs for children with attention-deficit/hyperactivity disorder. National estimates from the medical expenditure panel survey. Archives of Pediatrics and Adolescent Medicine 2002; 156: 504-511.
13. Barkley RA, Anastopoulos AD, Guevremont DC et al. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization, Journal of the American Academy of Child and Adolescent Psychiatry 1991; 30: 752-761.
14. Sayal K, Taylor E, Beecham J. Parental perception of problems and mental health service use for hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 1410-1414.
15. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 2001; 108: 1033-1044.
16. Greenhill LL, Pliszka S, Dulcan MK et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41 (Suppl 2): 26S-49S.
17. Conners CK, March JS, Frances A et al. Treatment of attention-deficit/ hyperactivity disorder: expert consensus guidelines. Journal of Attention Disorders 2001; 4 (Suppl 1): S1-S128.
18. Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. Journal of Child and Adolescent Psychopharmacology 2001; 11: 59-67.
19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001; 23: 1296-1310.
20. Marchetti A, Magar R, Lau H et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clinical Therapeutics 2001; 23: 1904-1921.
21. Tulloch SJ, Zhang Y, McLean A, Wolf KN. SLI381 (Adderall XR), a two-component, extended-release formulation of mixed amphetamine salts: bioavailability of three test formulations and comparison of fasted, fed, and sprinkled administration. Pharmacotherapy 2002; 22: 1405-1415.
22. McCracken JT, Biederman J, Greenhill L et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 673-683.
23. Biederman J, Lopez FA, Boellner SW et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110: 258-266.
24. Schipper H, Clinch J, Olweny C. Quality of Life Studies: Definitions and Conceptual Issues. New York: Lippincott-Raven, 1996.
25. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. New York: Lippincott-Raven, 1996.
26. Starfield B, Riley A. Profiling health and illness in children and adolescents. In: Drotar D, Editors. Measuring Health-Related Quality of Life in Children and Adolescents: Implications for Research and Practice. Mahwah, NJ: Erlbaum, 1998: 85-104.
27. Sawyer MG, Whaites L, Rey JM et al. Health-related quality of life of children and adolescents with mental disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 530-537.
28. Landgraf JM, Abetz L, Ware JE. The Child Health Questionnaire (CHQ): A User's Manual. Boston, MA: Health Institute, New England Medical Center, 1996.
29. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value in Health 1999; 2: 113-127.
30. Conners CK. Conners' Rating Scales-Revised: Technical Manual. North Tonawanda, NY: Multi-Health Systems, 1997.
31. Varni JW, Sied M, Kurtin PS. PedsQL™ 4.0: reliability and validity of the Pediatric Quality of Life inventory™ Version 4.0 Generic Core Scales in healthy and patient populations. Medical Care 2001; 39: 800-812.
32. Varni JW, Seid M, Smith Knight T et al. The PedsQL™ 4.0 Generic Core Scales: sensitivity, responsiveness, and impact on clinical decision-making. Journal of Behavioral Medicine 2002; 25: 175-193.
33. Guy W. Clinical Global Impressions (CGI). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, 1976: 218-222.
34. SAS Institute. SAS/STAT Software: Changes and Enhancements Through Release 6.12. SAS Institute, Cary, NC, 1997.
35. Hirshey Dirksen SJ, D'Imperio JM, Birdsall D et al. A postmarketing clinical experience study of Metadate® CD. Current Medical Research and Opinion 2002; 18: 371-380.
36. Pliszka SR, Lopez M, Crismon ML et al. A feasibility study of the Children's Medication Algorithm Project (CMAP) algorithm for the treatment of ADHD. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 279-287.
37. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry 1999; 56: 1073-1086.
38. Horrigan JP, Kohli RR. The impact of dosing frequency on psychostimulant compliance in ADHD. Poster presented at: 42nd Annual New Drug Clinical Evaluation Unit (NCDEU) Meeting, Boca Raton, June 11, 2002.
39. McGough JJ, Biederman J, Greenhill LL et al. Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 684-691.
40. DeVeaugh-Geiss J, Conners CK, Sarkis EH et al. GW320659 for the treatment of attention-deficit/hyperactivity disorder in children. Journal of the American Academy of Child and Adolescent Psychiatry 2002; 41: 914-920.
41. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: e83.